Global Blood Therapeutics Inc $ 47.89 -0.36 (-0.77%)
Volume:
947,570
Avg Vol (1m):
1,175,998
Market Cap $:
2.96 Bil
Enterprise Value $:
2.59 Bil
P/E (TTM):
0.00
P/B:
6.44
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 3.35 | ||
| Equity-to-Asset | 0.66 | ||
| Debt-to-Equity | 0.35 | ||
| Debt-to-EBITDA | -0.55 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | 5.49 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -344.28 | ||
| Net Margin % | -332.94 | ||
| ROE % | -51.9 | ||
| ROA % | -38.3 | ||
| ROC (Joel Greenblatt) % | -393.57 | ||
| 3-Year EBITDA Growth Rate | -24.8 | ||
| 3-Year EPS without NRI Growth Rate | -22.6 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 6.44 | ||
| PS Ratio | 34.68 | ||
| EV-to-EBIT | -8.68 | ||
| EV-to-EBITDA | -9.01 | ||
| EV-to-Revenue | 30.59 | ||
| Current Ratio | 7.63 | ||
| Quick Ratio | 7.2 | ||
| Days Inventory | 6577.65 | ||
| Days Sales Outstanding | 60.95 | ||
| Days Payable | 2681.2 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 6.45 | ||
| Earnings Yield (Greenblatt) % | -11.54 |